Canada Markets closed

Mesoblast Limited (MEOBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.57490.0000 (0.00%)
At close: 03:26PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.5749
Open0.5749
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.5749 - 0.5749
52 Week Range0.4400 - 0.8600
Volume10
Avg. Volume26
Market Cap540.12M
Beta (5Y Monthly)2.49
PE Ratio (TTM)N/A
EPS (TTM)-0.1740
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Designation for Rexlemestrocel-L in Chronic Low Back Pain

    NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA)

  • GlobeNewswire

    Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

    Validation of Remestemcel-L Potency Assay used in the Phase 3 Trial which Measures In-Vivo Activity based on Mechanism of Action Assay Identifies High-Potency Product Lots Associated with Enhanced Survival New Data Show that Remestemcel-L Improves Inflammatory Biomarkers and Survival in Children at Highest Risk of Mortality New 4-Year Data from the Phase 3 Trial Shows Durable Long-Term Survival Outcomes BLA Resubmission will have a Review Period up to Six-Months from Filing upon Acceptance by FD

  • GlobeNewswire

    Appendix 4C Quarterly Activity Report

    Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2022NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2022. Financial Highlights Revenue from royalties on sales of TEMCELL® HS Inj.1 sold in Japan by our licensee for the quarter increased 36% to US$1.9 million from US$1.4 million for